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Health related quality of life in patients with
multiple myeloma undergoing a double
transplantation
Multiple myeloma is a diffuse neoplasm of bone
marrow plasma cells in which the malignant cells
mingle with normal haematopoietic cells through-
out the red bone marrow. Most frequent compli-
cations of multiple myeloma are painful pathologic
fractures, anaemia, hypocalcaemia, renal failure
and recurrent bacterial infections (1–3). Obviously,
the subjective experience of numerous symptoms
caused by these complications reduces the ability
of normal functioning and negatively influences
patients quality of life.
Despite intensive research for several decades,
cure is not presently attainable with standard
chemotherapy, interferon or even with high-dose
chemotherapy supported by autologous transplan-
tation regimens with bone marrow or peripheral
blood stem cells (4–5). Only a small number of
patients, for whom a human leucocyte antigen
(HLA) identical sibling donor is available, reach
long-term remission and, apparently, cure after
allogeneic grafting. Thus multiple myeloma is
uniformly lethal with a median survival of <4 yr
in most studies (5–7). High-dose therapy with stem
cell support results in high rates of response, but in
general responses are not long lasting (8–9) and
survival plateaus do not appear (10). Because of the
poor prognosis for long-term (disease-free) survival
in myeloma patients and the fact that there are no
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Abstract: Objectives: To investigate the subjective well-being of
patients with newly diagnosed multiple myeloma who were treated in a
tandem transplantation programme. Methods: Fifty-one patients
participated in the prospective, longitudinal questionnaire study. The
EORTC QLQ-C30 and the EuroQol-5D were administered 2 wk after
completion of vincristine, adriamycin and dexamethason/vincristine,
adriamycin and methyl prednison (VAD/VAMP) chemotherapy, both at
hospital discharge after treatment with high-dose melphalan (HDM)
and 1 month after this hospital discharge, at hospital admission,
at the day of hospital discharge for peripheral stem cell transplantation
(PSCT) and at 6 and 12 months following discharge after
PSCT. Results: Overall, patients functioning improved during treat-
ment and follow-up, with significant decreases shortly following PSCT.
Shortly after HDM and PSCT, patients reported a considerable increase
in levels of soreness in the mouth (+26/+36 points on a scale ranging
form 0 to 100; P < 0.01), change of taste (+23/+21 points; P < 0.05/
NS), nausea/vomiting (+26/+27 points; P < 0.01/< 0.05), appetite
loss (+40/+43 points; P < 0.001) and diarrhoea (+25/+36 points;
P < 0.01). However, none of these symptoms persisted during follow-
up. Conclusion: The intensive treatment programme was subjectively
being well tolerated by the majority of patients. The duration of declined
quality of life after administration of HDM seemed to be short. The
duration of subjective recovery after PSCT remained uncertain, but in
any case was present at the 6 month follow-up. Together with the rather
good results in survival, the evaluation of quality of life invites further
exploration of double transplantations in multiple myeloma.
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major survival differences between existing treat-
ments, quality of life should be an important
consideration in the choice of treatment.
In an attempt to improve prognosis in myeloma,
several studies are now being performed using total
therapy as an approach. This involves a strategy of
two (or more) high-dose therapy and rescue proce-
dures (11–13). In the VU University Medical
Centre, Amsterdam, such a double-transplant
treatment programme has been applied for several
years. We explore a protocol using vincristine,
adriamycin and dexamethason (VAD) induction
therapy, followed by high-dose melphalan (HDM)
(140 mg/m2) and whole blood stem cells. Thereaf-
ter, stem cells are harvested by leucapheresis and a
second stem cell transplantation is performed after
busulphan (16 mg/kg) and cyclophosphamide
(120 mg/kg). For those patients who progress to
the second transplantation, the median overall
survival is 84 months (range 14–152), rated from
the time of diagnosis (14).
The aim of the current quality of life study was to
evaluate the subjective well-being of patients par-




All patients scheduled for intensive treatment of
multiple myeloma in the VU University Medical
Centre, Amsterdam, the Netherlands between
March 1997 and December 1998 were requested
to participate in the quality of life study. In
addition, the collaboration was asked of patients
who already started treatment, but who had not yet
passed the last two measurement points for quality
of life. The total study population for quality of life
consisted of 51 patients: 35 patients from the start
of the protocol and 16 patients who took in later.
These latter patients all started treatment between
March 1995 and September 1996.
All patients referred to the hospital who were
<65 yr of age with or without prior treatment for
multiple myeloma were eligible for the intensive
treatment programme. Exclusion criteria were
severely abnormal cardiac or pulmonary function,
serum creatinin above 250 lmol/L, serum biliru-
bin above 35 lmol/L, alanine-aminotransferase
(ALAT) and/or aspartate-aminotransferase (ASAT)
above four times normal, other severe non-haema-
tological disease, or refusal to participate.
All patientswere scheduled for the following treat-
ment protocol: two courses of VAD or vincristine,
adriamycin and methyl prednison (VAMP) chemo-
therapy,HDMfollowed by transplantation ofwhole
blood, collection of r-met Hu G-CSF mobilised per-
ipheral blood progenitor cells by leukapheresis and
finally high-dose chemotherapy (busulfan/cyclo-
phosphamide) followed by reinfusion of the previ-
ously collected peripheral stem cells (PSCT) (14).
The VU University Medical Centre is an aca-
demic hospital and the haematologists have a
consultation function for several local hospitals.
The policy of the haematologists is to treat referred
patients in the academic hospital when needed, but
in the referring hospital when possible. Because
VAD/VAMP chemotherapy can be given safely in a
non-academic hospital, most patients started their
treatment in a local hospital.
The questionnaire
Both the EORTC QLQ-C30 and the EuroQol 5-D
were used in this study. The EORTC QLQ-C30 (15)
is a cancer-specific questionnaire. It consists of five
functional scales (physical, role, emotional, cogni-
tive and social functioning), three symptom scales
(fatigue, pain and nausea/vomiting), six single items
(dyspnoea, appetite loss, sleep disturbance, consti-
pation, diarrhoea and financial impact of disease)
and one global health and quality of life scale. All
scores can be linearly transformed into a scale
ranging from 0 to 100. Higher scores on the
functioning scales represent higher levels of func-
tioning, whereas higher scores on the symptom
scales represent a higher level of complaints. The
questionnaire is available in many languages and its
reliability and validity in myeloma patients has been
proven in a large Scandinavian study (16). At the
time the current study started, there was not yet a
myeloma specific module of the EORTC question-
naire available. Therefore, some disease and treat-
ment specific items were added by the researchers.
These items were formulated in collaboration with
haematologists and tested on a limited number of
patients for clarity and relevance in another study in
myeloma patients performed by the institute for
Medical Technology Assessment (iMTA). The items
are presented in Appendix and had the same format
as the items of the EORTC QLQ-C30.
The EuroQol-5D was included in this study
because of its ability to express health related
quality of life in one summarised number, which
can be used as a utility value in economic evalu-
ations. It is a generic instrument, which measures
five dimensions: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression (17). In the
descriptive part the patient is required to rate his or
her health on each of the five dimensions by
checking one of the three levels of severity: no
problems, some/moderate problems or severe
problems. The EQ-5D Index assigns a preference
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value (utility) to each health state generated by the
descriptive part of the questionnaire. The prefer-
ence weights used in this study have been obtained
from a sample of the general population in the UK
by using the time trade-off procedure (18).
Data collection
Seven time points for measurement of quality of life
were defined:
1 baseline ¼ 2 wk after completion of VAD/
VAMP therapy;
2 the day of hospital discharge after HDM;
3 1 monthafterhospital discharge followingHDM;
4 the day of hospital admission for PSCT;
5 the day of hospital discharge following PSCT;
6 6 months after hospital discharge following
PSCT;
7 12 months after hospital discharge following
PSCT.
Unfortunately, the fact that most patients started
their treatment in a diversity of local hospitals
made a pretreatment measurement too complica-
ted. The questionnaires were either handed to the
patients on the hospital ward in case they were
hospitalised or mailed to the patients home.
Reminders were sent when questionnaires were
not returned within 1 month.
Statistical methods
The paired-samples t-test was used to examine
whether there were significant changes in quality of
life during treatment and follow-up, compared with
baseline values. Thus, the main analyses were only
based on the patients who completed the baseline
questionnaire. To investigate whether the QoL of
these patients differed from the patients who failed
to complete the baseline questionnaire, absolute
scores of both groups on all the other time-points
were compared by using the student’s t-test.
Differences of 10 points or more on the 0–100
scale were considered to be clinically relevant (19,
20). Changes in scores of <10 points were
supposed not to be relevant and therefore not
statistically tested. The statistical software SPSS for
windows version 10.0 was used.
Results
Of the 36 patients who entered the treatment
programme between March 1997 and December
1998, one refused to take part in the quality of life
study. This patient found the completion of the
questionnaires too much a burden.
The mean age of the participants at the start of
treatment was 53 yr (median 54; range 31–65).
Patient characteristics and remission status after
treatment are shown in Table 1.
The mean duration of the whole treatment
programme from start VAD/VAMP until hospital
discharge after PSCT for patients who completed
the whole programme was about 12 months.
Eleven patients never proceeded to PSCT because
of disease progression (n ¼ 4), insufficient recovery
after HDM (n ¼ 1), patient refusal (n ¼ 2), anti-
coagulant therapy (n ¼ 1) or insufficient harvest of
stem cells (n ¼ 3).
Response to questionnaires
A total of 205 questionnaires was completed. The
response rate varied from 71% after VAD/VAMP
to 98% at hospital discharge following HDM. The
number of completed questionnaires at each point
in time is shown in Table 2.
The response rate was calculated as the propor-
tion of completed questionnaires of the total
number that had to be filled out at each time-
point. Reasons for non-applicability were:
• patient had already passed this time point when
he/she entered the study: n ¼ 16 at T1, n ¼ 15 at
T2, n ¼ 11 at T3, n ¼ 8 at T4, n ¼ 7 at T5;
• patient died: n ¼ 1 at T5, n ¼ 2 at T6, n ¼ 5 at
T7;
• patient did not proceed to PSCT: n ¼ 11 at T4,
T5, T6 and T7.
Reasons for missing questionnaires were logistical
problems for the measurement after VAD/VAMP
(because of treatment in local hospitals), question-
naires were not handed to the patient at the hospital
ward (n ¼ 15) or refusal by the patient (n ¼ 18).
An overview of the available quality of life
questionnaires and patterns of missing data is given
in Table 3.
From Table 3 it can be read that the number of
patients who could be included in the main analysis
(change scores from baseline) declines from 24
1 month after hospital discharge for HDM to 12 at
12 months following discharge after PSCT. These
small numbers of patients reduce the likeliness of
statistical significance, even for relatively large
differences in change scores.
The EORTC QLQ-C30
High-dose melphalan did not seem to have a major
impact on patients functioning scores in the short-
term. At the time of hospital discharge (at a median
of 17 d after administration of HDM) the level of
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functioning was comparable to that at baseline.
One month after discharge, even a significant
improvement in physical (P < 0.01), role
(P < 0.05) and social (P < 0.05) functioning was
reported. At the time of admission for PSCT (at a
median time of 9 months after HDM) a further
improvement in global quality of life (P < 0.05)
was seen. As could be expected, an enormous
decline in the level of functioning was observed by
the time of discharge following PSCT. At 6 and
12 months after PSCT, physical, role and social
functioning were higher than at baseline.
Regarding the symptoms measured by the QLQ-
C30, there was a considerable increase in levels of
appetite loss (P < 0.01), diarrhoea (P < 0.01) and
nausea/vomiting (P < 0.01) after the administra-
tion of HDM and after PSCT. These symptoms did
not persist during follow-up. Mean change scores
from baseline for selected variables are presented in
Table 4.
Treatment and disease specific items
After VAD/VAMP, patients complained most
about diminished sexual interest (mean absolute
score ¼ 52), pain in the back (mean absolute
score ¼ 43) and bone pain (mean absolute
score ¼ 35). Although diminished sexual interest
showed a mean decrease of 22 points (NS) at
12 months follow-up, the problem remained pre-
sent in many patients.
Once patients had received HDM, the level of
bone pain declined significantly (P < 0.05). How-
ever, this decline did not remain to this extent
during further treatment and follow-up. Pain in the
back also showed a decline, but the mean change
score was only significant shortly after HDM and
PSCT and the mean absolute score was still 32 after
12 months of follow-up.
The intensity of soreness in the mouth (P < 0.01)
and change of taste (P < 0.05) increased after
administration of HDM and after PSCT, but most
patients were no longer bothered by these symp-
toms at 1 month after HDM and at 6 months after
PBCT. Mean change scores for selected symptoms
are shown in Table 4 and in Fig. 1.
EuroQol utilities
At baseline, the combination of problems on the
five EuroQol dimensions correspond to a mean
Table 1. Patient characteristics and response to treatment





Mean (SD) 53 (8.2) 53 (7.2)
Median (min/max) 55 (31/65) 54 (31/65)
Sex [n (%)]
Male 16 (64) 31 (61)
Female 9 (36) 20 (39)
Stage Salmon and Durie [n (%)]
Ia 8 (32) 12 (24)
IIa 1 (4) 4 (8)
IIIa 15 (60) 32 (63
IIIb 1 (4) 3 (6)
Remission status after HDM1 [n (%)]
Complete remission 7 (28) 13 (25)
Partial remission 8 (32) 16 (31)
Improvement 1 (4) 7 (14)
No response 8 (32) 13 (25)
Toxic death 1 (4) 1 (2)
Unknown 1 (2)
Remission status after PSCT1 [n (%)]
Complete remission 5 (20) 11 (22)
Partial remission 8 (32) 15 (29)
Improvement 2 (8) 8 (16)
No response 2 (8) 3 (6)
Toxic death 1 (2)
1Complete remission, complete disappearance of monoclonal proteins on immu-
nofixation, <5% plasma cells in the bone marrow and stable skeletal lesions; partial
remission, >75% reduction in monoclonal proteins; improvement, a reduction be-
tween 50% and 75%. No response represents a reduction of <50%. Toxic death,
death within 3 months of transplantation.
Table 2. Response to questionnaires by measurement
T1 T2 T3 T4 T5 T6 T7
Completed 25 31 39 27 26 31 26
Missing 10 5 1 5 5 7 9
Not applicable 16 15 11 19 19 13 16
Total 51 51 51 51 51 51 51
Response rate 0.71 0.86 0.98 0.84 0.84 0.82 0.74
T1, after VAD/VAMP; T2, discharge HDM; T3, 1 month after HDM; T4, admission
PBSCT; T5, discharge PBSCT; T6, 6 months follow-up; T7, 12 months follow-up.
Table 3. Available quality of life questionnaires and patterns of missing data
T1 T2 T3 T4 T5 T6 T7 Frequency
* * * * * * * 10
* * * * * * 3
* * * 9
* * * * * 1
* * 1
* * * * * 1
* * * * * * 2
* * * * 1
* * * 2
* * 4
* * * * * 1
* * * * 2
* * * 1
* * 1
* 1
* * * * 3
* * * 1
* * 6
* 1
T1, baseline (after VAD/VAMP); T2, discharge HDM; T3, 1 month after HDM; T4,
admission PBSCT; T5, discharge PBSCT; T6, 6 months follow-up; T7, 12 months
follow-up.
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health utility index of 0.52 on a scale ranging from
0 (death) to 1 (full health). An increase in mean
utility is observed from the time point 1 month
after discharge onwards, with a temporary decrease
at hospital discharge after PSCT and a maximum
increase of 0.17 at 12 months follow-up (P ¼ 0.06).
Absolute QoL values
To check whether there were differences in QoL
between patients who completed the baseline ques-
tionnaire and the other patients, their mean abso-
lute scores on all dimensions and symptoms were
compared at every time-point. No relevant/signifi-
cant differences were observed.
However, absolute scores of patients at 6 and
12 months follow-up were better than is being
suggested by mean change scores from baseline in
Table 4. For example, the mean absolute score at
12 months follow-up for physical functioning is 85,
whereas a mean score of 70 is suggested (mean
baseline score is 50, mean change score from
baseline ¼ 20). The absolute scores at baseline
and 12 months follow-up are shown in Table 5.
Discussion
In our quality of life study, we found an improve-
ment in subjective well-being for patients who were
able to complete the treatment programme. This
improvement was not only found in analysing the
cancer specific EORTC QLQ-C30 questionnaire
and myeloma specific symptoms, but also in
(generic) EuroQol-5D utilities.
This was a single centre, non-randomised study,
so patient selection cannot be excluded. However,
the advantage of such data is that they reflect real
clinical practice. The number of patients in the
main analyses was small. This was because only
patients with a baseline assessment could be inclu-
ded to calculate change scores from baseline. The
fact that mean absolute scores on all the other time-
points did not differ between patients with or
without a baseline measurement, suggests that the
results are also valid for the whole study population
of 51 patients. The patient numbers in the analyses
were further reduced by missing questionnaires. If
non-response to questionnaires is selective, the
results might be under- or overestimated. We have
no reasons to assume that the non-response to
questionnaires in our study was selective. Reasons
for missing questionnaires were not always known.
In any case, response to questionnaires was not
related to objective disease state (remission or
progressive disease). So, selection of patients in
better clinical condition seems unlikely.
Unfortunately, our baseline measurement was
not a pretreatment assessment. Because of logistic
problems, a pretreatment measurement was not
possible. Because VAD/VAMP chemotherapy is
known for its rapid tumour reduction (21), it can be
assumed that pretreatment levels of quality of life
were lower compared with our baseline measure-
ment after VAD/VAMP. This means that the real
Table 4. Mean absolute scores (SD) at baseline
















EORTC QLQ-C30 functioning scales
Physical functioning 50 (28) )2 13** 13* )19* 13* 20*
Role functioning 41 (29) 2 18** 14 )26** 19* 20
Emotional functioning 72 (22) 3 10* 6 0 0 1
Cognitive functioning 76 (25) )11 8 1 )6 3 3
Social functioning 59 (30) 5 12 6 )23* 10 13*
Global QoL 58 (23) )11* 3 10* )17** 7 4
EORTC QLQ-C30 symptoms
Fatigue 55 (29) 7 )15* )13 10 )13 )6
Nausea/vomiting 11 (25) 26** 2 )1 27* )1 4
Pain 37 (29) )7 )8 )10 4 )9 )11
Appetite loss 22 (31) 40** 2 )4 43** )4 )3
Diarrhoea 18 (31) 25** )1 0 36** )2 3
Disease/treatment related symptoms
Pain in the back 43 (37) )6 )14* )7 )21* )7 )11
Soreness of the mouth 9 (20) 26** 1 )11 36** )2 )6
Change in taste 20 (32) 23* 6 )9 21 )4 )8
Diminished sexual interest 52 (40) 11 )1 )27* )12 )20 )22
Pain in the bones 35 (35) )20* )4 )7 )21* )9 )6
EuroQol utility 0.52 (0.33) 0.03 0.14* 0.14 )0.14 0.12 0.17
*P < 0.05; **P < 0.01.
For the functioning scales and the EuroQol a negative change score means a deterioration in functioning/utility,
whereas for the symptoms a negative change score reflects a lower level of symptoms.
T2, discharge HDM; T3, 1 month after HDM; T4, admission PSCT; T5, discharge PSCT; T6, 6 months follow-up; T7,
12 months follow-up.
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improvement in quality of life during therapy is
likely to be underestimated in our study.
As expected, the largest decline in quality of life
was observed at the time of hospital discharge
following HDM and PSCT. These declines were
obviously treatment related. Patients reported
improvements at 1 month after HDM and at
6 months after PSCT. Because there were no
measurements between discharge and 6 months
after discharge following PSCT, more precise
statements about the time to subjective recovery
after PSCT cannot be made.
With low mean absolute scores at baseline and
small mean change scores during treatment and
follow-up, many of the disease and treatment
specific symptoms we added to the questionnaire
were not relevant; at least, not at the time points of
measurement. By now, an official EORTC myel-
oma module has been developed and is being
validated in a number of international studies (22).
Not surprisingly, this module has some overlapping
with the items we selected.
It is difficult to compare our results with other
studies. There is a lack of longitudinal studies in this
patient group. In a Scandinavian study (also non-
randomised) quality of life was measured before and
after high-dose melpalan with autologous blood
stem-cell support (23). Although different from our
patients (only one transplantation and analysis on
intention to treat basis where 78% of patients
actually proceeded to HDM), the absolute EORTC
QLQ-C30 scores of 12 months after start of induc-
tion therapy with VAD courses, which corresponds




























Fig. 1. (A) Mean change scores for preselected functional
dimensions. (B) Mean change scores for preselected symp-
toms. T2, discharge HDM; T3, 1 month after HDM; T4,
admission PSCT; T5, discharge PSCT; T6, 6 months follow-
up; T7, 12 months follow-up.
Table 5. Mean absolute scores (SD) at baseline
and at 12 months follow-up for the patients
who proceeded to PSCT and 12 months follow-up
Baseline – Patients who
proceeded to 12 months
follow-up (n ¼ 12)
12 months follow-up –
Patients with baseline
(n ¼ 12)
12 months follow-up –
All patients (n ¼ 26)
EORTC QLQ-C30 functioning scales
Physical functioning 65 (28) 85 (15) 78 (19)
Role functioning 53 (32) 72 (18) 71 (21)
Emotional functioning 74 (19) 74 (20) 78 (19)
Cognitive functioning 79 (21) 82 (21) 85 (17)
Social functioning 69 (27) 82 (25) 82 (25)
Global QoL 66 (23) 70 (16) 69 (19)
EORTC QLQ-C30 symptoms
Fatigue 42 (30) 35 (27) 30 (26)
Nausea/vomiting 1 (5) 6 (13) 3 (9)
Pain 28 (30) 17 (17) 15 (16)
Appetite loss 6 (13) 3 (10) 1 (7)
Diarrhoea 0 (0) 3 (10) 1 (7)
Disease/treatment related symptoms
Pain in the back 31 (39) 19 (17) 22 (19)
Soreness of the mouth 11 (22) 6 (13) 4 (11)
Change in taste 14 (22) 6 (13) 7 (22)
Diminished sexual interest 56 (38) 33 (40) 40 (38)
Pain in the bones 19 (30) 14 (17) 17 (7)
EuroQol utility 0.60 (0.33) 0.77 (0.13) 0.79 (0.18)
For the functioning scales and the EuroQol a negative change score means a deterioration in functioning/utility,
whereas for the symptoms a negative change score reflects a lower level of symptoms.
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with the absolute scores of our patients at 6 months
after PSCT. In addition, the EORTC scores of our
heavily treated patient group were not worse than
those of myeloma patients in a large Nordic study
who were treated with oral melphalan/prednison
(16). This is known as a much less toxic therapy, but
the patients were of a higher age (median 67).
Because our time points for measurement of
quality of life were related to the actual treatment,
we were able to gain insight into the toxicity of the
various phases of treatment. In a comparative trial
with analysis on intention to treat basis, fixed time
points from start of treatment might be preferable,
but in our explorative study the choice for treat-
ment related time points seems valid.
Absolute scores of patients at 6 and 12 months
follow-up were better than is being suggested by
mean scores. This is observed in several dimensions
and finds its explanation in the fact that patients
who did not proceed to PSCT and 12 monts had
poorer quality of life at baseline, This may imply
that quality of life at diagnosis might have a
prognostic value for treatment outcome. The
association between baseline quality of life values
and survival has already been described by Wisloff
and Hjorth (24). The number of patients in our
study was too small for detailed analyses, but this
topic might be interesting for future studies.
We conclude that patients who are able to
complete the programme show a considerable
improvement in quality of life. Because of small
patient numbers many of the differences are not
statistically significant, but the trend towards
improved functioning and reduced symptoms is
obvious. This means that the intensive treatment
programme is subjectively being tolerated well in
the majority of patients. Together with the rather
good results in survival, the evaluation of quality of
life invites to further exploring double transplanta-
tions in multiple myeloma.
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Appendix. Additional questions concerning multiple myeloma and treatment
related symptoms. Have you, during the past week, been bothered by:
Not at all A little Quite a bit Very much
1 Dizziness? 1 2 3 4
2 Palpitations? 1 2 3 4
3 Pain in the chest? 1 2 3 4
4 Pain in the back? 1 2 3 4
5 Pain in the arms? 1 2 3 4
6 Pain in the legs? 1 2 3 4
7 Thirst? 1 2 3 4
8 Sleepiness? 1 2 3 4
9 Fever? 1 2 3 4
10 Weakness in arms/legs? 1 2 3 4
11 Tingling of hands/feet? 1 2 3 4
12 Numbness in arms/legs? 1 2 3 4
13 Haematomas? 1 2 3 4
14 Soreness of the mouth? 1 2 3 4
15 Myalgia? 1 2 3 4
16 Shivers? 1 2 3 4
17 Perspiration? 1 2 3 4
18 Change of taste? 1 2 3 4
19 Diminished sexual interest? 1 2 3 4
20 Headache? 1 2 3 4
21 Loss of hair? 1 2 3 4
22 Gum bleeding? 1 2 3 4
23 Epistaxis? 1 2 3 4
24 Bone pain/joint pain? 1 2 3 4
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